Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition

Liver International

Volumn 35, Issue 4, 2015, Pages 1383-1392

  Pauta, Montse ^a   Ribera, Jordi ^a   Melgar Lesmes, Pedro ^a   Casals, Gregori ^a,b   Rodríguez Vita, Juan ^a   Reichenbach, Vedrana ^a   Fernandez Varo, Guillermo ^a   Morales Romero, Blai ^b   Bataller, Ramon ^c   Michelena, Javier ^d   Altamirano, Jose ^d   Jiménez, Wladimiro ^a,b,d   Morales Ruiz, Manuel ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Angiopoietins; Chronic liver disease; CVX 060; Liver sinusoidal endothelial cells; Portal hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTIBODY; CD11B ANTIGEN; CD3 ANTIGEN; CVX 060; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANGPT2 PROTEIN, HUMAN; ANTIBODY CONJUGATE; AUTACOID; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MICROVASCULATURE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STELLATE CELL; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; UPREGULATION; VASCULARIZATION; WISTAR RAT;

ADULT; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNOCONJUGATES; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; RATS, WISTAR; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84924591909     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12505     Document Type: Article

References (41)

1. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
2. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
3. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-85.
4. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103: 4150-6.
5. Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002; 110: 1619-28.
6. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
7. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
8. Reiss Y, Droste J, Heil M, et al. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 2007; 101: 88-96.
9. Seegar TC, Eller B, Tzvetkova-Robev D, et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010; 37: 643-55.
10. Song SH, Kim KL, Lee KA, Suh W. Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells. Biochem Biophys Res Commun 2012; 419: 281-6.
11. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 411-23.
12. Daly C, Eichten A, Castanaro C, et al. Angiopoietin-2 functions as a tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73: 108-18.
13. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-23.
14. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-13.
15. Tanaka S, Mori M, Sakamoto Y, et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341-5.
16. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: S38-53.
17. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008; 12: 939-62.
18. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56.
19. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-26.
20. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
21. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-81.
22. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-9.
23. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005; 314: 738-44.
24. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286: 2511-4.
25. Huang H, Lai JY, Do J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17: 1001-11.
26. Reichenbach V, Ros J, Fernandez-Varo G, et al. Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems. J Pharmacol Exp Ther 2012; 340: 629-37.
27. Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G, et al. Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair 2011; 4: 19.
28. Van Steenkiste C, Ribera J, Geerts A, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011; 53: 1629-40.
29. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004; 204: 1-10.
30. Lukasz A, Hellpap J, Horn R, et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008; 12: R94.
31. Kumpers P, Van Meurs M, David S, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care 2009; 13: R64.
32. Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701.
33. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-300.
34. Hadem J, Bockmeyer CL, Lukasz A, et al. Angiopoietin-2 in acute liver failure. Crit Care Med 2012; 40: 1499-505.
35. Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF III. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci USA 2003; 100: 5396-400.
36. Cao Y, Sonveaux P, Liu S, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007; 67: 3835-44.
37. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009; 175: 2159-70.
38. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999; 31: 1120-30.
39. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol 2005; 77: 487-95.
40. Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-38.
41. Rosen LS, Mendelson DS, Cohen RB, et al. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010; 28: 2524.